LMRI

LMRI remains in a Stage 2 advance with key EMAs sloping up. The recent corrective pullback into the 9/21 EMA zone has not breached intermediate structure, sustaining a medium-term bullish bias. However, short-term signals lack a clear reversal, so we defer execution and stalk for a decisive pullback interaction at the EMAs before engaging.

• ↑Q1 revenue $253 M (+3% YoY), advanced modalities grew 7%.
• ↑PET volumes jumped 23.1% and MRI rose 8.2% YoY.
• ↓Negative profitability score; operating cash flow ~$3 M pressures margins.